Efficacy & Safety of SCH 900435 in Schizophrenia (Study P06079)(WITHDRAWN)
Status:
Withdrawn
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess whether SCH 900435 (Org 25935) 16 mg twice daily is
more effective than placebo in the treatment of patients with schizophrenia, using olanzapine
15 mg once daily as active control.